Clinical trial
Targeted Treatment Based on ctDNA Genotyping Combined With Tislelizumab and HAIC as Salvage Treatment for Advanced Colorectal Cancer Liver Metastasis Failed From Standard Systemic Treatment (SALVLIV Trial)
NCT06199232 is registered in ClinicalTrials.gov with Peking University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Targeted Treatment Based on ctDNA Genotyping Combined With Tislelizumab and HAIC as Salvage Treatment for Advanced Colorectal Cancer Liver Metastasis Failed From Standard Systemic Treatment (SALVLIV Trial)
- Lead sponsor
- Peking University
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- January 23, 2024
- Completion date
- July 10, 2026
- Enrollment
- 47 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ctdna genotype, failed from standard treatment, liver metastasis colon cancer, mss